News

Pushing the Boundaries of Possibility

Read the latest company news and learn about the ground-breaking science behind our company.

News

28-7 Therapeutics raises $65M for cancer drugs aimed at tumor-suppressing RNAs

Founded in 2016, the company’s core technology comes from four Harvard Medical School professors in biological chemistry, molecular pharmacology and RNA medicine: Richard Gregory, Ph.D.; Frank Slack, Ph.D.; Piotr Sliz, Ph.D.; and George Daley, M.D., Ph.D., dean of the faculty of medicine—who have collaborated for years on the role of noncoding RNAs in disease and identifying related protein targets.